Paccaud M F, Hazeghi P, Bourquin M, Maurer A M, Steiner C A, Seiler A J, Helbling P, Zimmermann H
Laboratoire de virologie, Direction de la santé publique, Genève.
Soz Praventivmed. 1995;40(2):72-9. doi: 10.1007/BF01360321.
Two studies are presented. The first one concerns a mumps outbreak in a kindergarten in Geneva in June 1991. Of 26 children, nine (34.6%) got mumps. Of nine children vaccinated with the Rubini vaccine strain, seven had the disease as opposed to only one of 14 children vaccinated with the Urabe strain. The vaccine efficacy of the Rubini strain was estimated at 22% with a 95% confidence interval of -10% to 45%. The second study concerns a cluster of 112 mumps patients seen by a pediatrician in the Bernese Jura region between September 1992 and May 1993. A case-control study was carried out resulting in a vaccine efficacy estimate of 50% with a 95% confidence interval of -19% to 81%. Of the cases, 51 (45.5%) had been vaccinated against mumps, 50 of them (98%) with the Rubini vaccine strain. Of the controls, 30 (61.2%) had been vaccinated, 86.7% of them with Rubini. Methodological problems of case selection and their possible effects on the estimated vaccine efficacy are discussed. The results of these two studies have been confirmed by more recent investigations. In retrospect, we therefore conclude that small studies can serve as early indicators for epidemiological evidence and that they can be finally integrated into a more complete picture.
本文介绍了两项研究。第一项研究涉及1991年6月日内瓦一所幼儿园爆发的腮腺炎疫情。在26名儿童中,9名(34.6%)感染了腮腺炎。在9名接种鲁比尼疫苗株的儿童中,7名患病,而在14名接种尿嘧啶疫苗株的儿童中只有1名患病。鲁比尼疫苗株的疫苗效力估计为22%,95%置信区间为-10%至45%。第二项研究涉及1992年9月至1993年5月期间伯尔尼汝拉地区一名儿科医生诊治的112例腮腺炎患者群。开展了一项病例对照研究,得出疫苗效力估计值为50%,95%置信区间为-19%至81%。在病例中,51名(45.5%)接种过腮腺炎疫苗,其中50名(98%)接种的是鲁比尼疫苗株。在对照中,30名(61.2%)接种过疫苗,其中86.7%接种的是鲁比尼疫苗。讨论了病例选择的方法学问题及其对估计疫苗效力可能产生的影响。这两项研究的结果已得到近期调查的证实。因此,我们回顾性地得出结论,小型研究可作为流行病学证据的早期指标,最终可融入更完整的情况中。